Vical to Present Update On Pandemic Influenza
Vaccine Program and Overview of Pivotal Phase 3
Melanoma Trial At ASGT ConferenceSAN DIEGO,
May 27, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated
(Nasdaq:VICL) today announced that the company will
be presenting at a series of upcoming conferences.
At the annual meeting of the
American Society of Gene Therapy (San Diego,
CA, May 27 - 30):
* Vical's Executive Vice President of Product Development, Alain P.
Rolland, Pharm.D., Ph.D., will provide a summary and status report
on the company's vaccine programs for both H5 (avian) and H1
(swine) strains of pandemic influenza; and
* Vical's Executive Director of Oncology Clinical Research, Linda G.
Strause, Ph.D., will provide an overview of the company's lead
cancer program, the Allovectin-7(r) Immunotherapy for Metastatic
Melanoma (AIMM) Phase 3 clinical trial.
About Vical
Vical researches and develops biopharmaceutical
products based on its patented DNA delivery
technologies for the prevention and treatment of
serious or life-threatening diseases. Potential
applications of the company's DNA delivery
technology include
DNA
vaccines for
infectious diseases or cancer, in which the
expressed protein is an immunogen; cancer
immunotherapeutics, in which the expressed protein
is an
immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an
angiogenic growth factor. The company is developing
certain
infectious disease vaccines and cancer
therapeutics internally. In addition, the company
collaborates with major pharmaceutical companies and
biotechnology companies that give it access to
complementary technologies or greater resources.
These strategic partnerships provide the company
with mutually beneficial opportunities to expand its
product pipeline and address significant
unmet
medical needs. Additional information on
Vical is available at
www.vical.com.
The Vical Incorporated logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains
forward-looking statements subject to risks
and uncertainties that could cause actual results to
differ materially from those projected.
Forward-looking statements include statements about
the company's focus, collaborative partners, product
candidates, and developmental status. Risks and
uncertainties include whether any product candidates
will be shown to be safe and efficacious in
clinical trials, the timing of clinical
trials, whether Vical or its collaborative partners
will seek or gain approval to market any product
candidates, the dependence of the company on its
collaborative partners, and additional risks set
forth in the company's filings with the Securities
and Exchange Commission. These forward-looking
statements represent the company's judgment as of
the date of this release. The company disclaims,
however, any intent or obligation to update these
forward-looking statements.
CONTACT: Vical Incorporated
Alan R. Engbring
(858) 646-1127
www.vical.com